Drug Profile
Research programme: orphan disease protein therapeutics - Alexion AstraZencea Rare Disease/Mitsubishi Tanabe Pharma
Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation; Synageva BioPharma
- Developer Alexion AstraZeneca Rare Disease; Mitsubishi Tanabe Pharma Corporation
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 23 Jun 2015 Synageva BioPharma has been acquired by Alexion Pharmaceuticals